A Stoichiometric Threshold, Not Just a Buildup: The Lamina's Farnesylated Species Ratio as a Tissue-Specific Aging Switch

The evidence for prelamin A/Lamin A processing decline as a unified driver of aging hallmarks is compelling. However, current models treat accumulation as a linear, dose-dependent toxin. This hypothesis challenges that view.

Core Hypothesis: Aging is not triggered by the absolute accumulation of farnesylated lamins, but by the disruption of a critical stoichiometric ratio between wild-type Lamin A and its farnesylated precursor (prelamin A/progerin). Tissue-specific aging manifests when this ratio crosses a tissue-defined threshold, acting as a master switch that converts the lamina from a structural/signaling hub into a pathological scaffold.

Mechanism: From Accumulation to Ratio-Dependent Phase Change

Current research notes tissue-specific accumulation rates of Lamin A [1]. The missing piece is how different cell types process this.

1. The Native State: In a young cell, wild-type Lamin A/C and a minor pool of farnesylated intermediates form a dynamic, functional lamina meshwork. This meshwork is stabilized by specific stoichiometric ratios—likely through dimerization or higher-order assembly domains—enabling proper chromatin tethering (LADs), DNA repair factor recruitment, and mechanosignaling [2,3].
2. The Threshold Crossing: ZMPSTE24 decline [4] increases prelamin A. Crucially, incorporation of farnesylated species into the lattice alters its biophysical properties (e.g., membrane affinity, stiffness). When the ratio of farnesylated to mature lamins exceeds a cell-type-specific threshold, the lamina undergoes a phase transition—from a dynamic gel to a rigid, hyper-affiliated scaffold. This new pathological structure:
   • Sequesters critical repair factors (e.g., 53BP1) away from DNA damage sites, exacerbating genomic instability.
   • Over-tethers specific chromatin domains, creating inflexible LADs that impair transcriptional plasticity and drive epigenetic drift (loss of H3K9me3, gain of H3K27me3) [2].
   • Activates p53/Rb not merely through lamina fragility, but via chronic mechanical stress signals from a rigid nucleus [3].
3. Tissue-Specificity Explained: Different tissues have different "critical ratios" based on:
   • Baseline expression of lamins (e.g., cardiomyocytes vs. fibroblasts).
   • Expression of other lamina proteins (e.g., Lamin B1, which may buffer or promote the transition).
   • Mechanical environment. A highly contractile cell like a cardiomyocyte may have a lower threshold for losing lamina flexibility than a chondrocyte.

Testable Predictions & Falsifiability

This model moves beyond correlation to testable biophysics.

• Prediction 1 (Biochemistry): In vitro reconstitution of the lamina meshwork with purified Lamin A and prelamin A will show a sharp, cooperative change in network elasticity or filament bundling at a specific molar ratio, not a gradual shift. This can be tested with atomic force microscopy or microrheology.
• Prediction 2 (Cell Biology): In aging cells or HGPS models, artificially overexpressing wild-type Lamin A should delay senescence and epigenetic drift more effectively than simply inhibiting prelamin A accumulation (e.g., with a farnesyltransferase inhibitor). It restores the ratio. This is a direct, competitive test of ratio vs. absolute amount.
• Prediction 3 (Tissue Level): Tissues with high lamin A expression (e.g., muscle, bone) will show the earliest evidence of the pathological phase transition in vivo with aging, preceding widespread dysfunction. This can be probed with tissue-specific proteomics and nuclear stiffness assays in young vs. old models.
• Falsification: If prelamin A accumulation causes aging hallmarks independently of its stoichiometry with wild-type Lamin A—i.e., if adding more wild-type Lamin A does not ameliorate the phenotype in a prelamin A-high context—the ratio model is false. The linear "toxin" model would hold.

Implications

If correct, this reframes therapeutic targets. Instead of broadly lowering prelamin A, we could aim to modulate the stoichiometry—perhaps via gene therapy to co-deliver ZMPSTE24 and Lamin A, or small molecules that stabilize the wild-type lattice. It also suggests the lamina is not just a hallmark controller, but the central processor whose output (a rigid vs. flexible nucleus) dictates the downstream hallmarks' progression.